EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Regression of liver fibrosis after HBsAg loss: A prospective matched case–control evaluation using transient elastography and serum enhanced liver fibrosis test

Lung-Yi Mak iD, Rex Wan-Hin Hui iD, Matthew S H Chung iD, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto iD, Man-Fung Yuen iD

Journal of Gastroenterology and Hepatology · 2024-12 · 39 (12) · 2826-2834

DOI: 10.1111/jgh.16728 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 26.08.2024. Verfasst von Lung-Yi Mak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Elasticity Imaging Techniques, Liver Cirrhosis, Hepatitis B Surface Antigens, Hepatitis B, Chronic. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Health and Medical Research Fund of the Hong Kong Special Administrative Region.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim We assessed the effect of hepatitis B surface antigen (HBsAg) seroclearance (HBsAg‐loss) on liver fibrosis regression in patients with chronic hepatitis B (CHB) infection.

Method

CHB patients with recent documented HBsAg‐loss were age‐ and gender‐matched with treatment‐naïve HBeAg‐negative CHB infection. Paired assessment with transient elastography and enhanced liver fibrosis (ELF) measurements were performed and repeated at 3 years. Fibrosis regression was arbitrarily defined as decrease in ≥ 1 fibrosis stage by ELF, or combining with reduction > 30% in liver stiffness.

Results

A total of 142 HBsAg‐loss and 142 CHB subjects were recruited (median age 58.1 years, 51.4% male). A total of 1.8% (1.4% HBsAg‐loss vs 2.1% CHB) achieved combined endpoint of fibrosis regression at 3 years. When ELF‐only definition of fibrosis regression was used, 14.5% HBsAg‐loss and 16.9% CHB subjects achieved this endpoint, which was significantly associated with baseline ELF (hazard ratio (HR) 1.827, 95% confidence interval (CI) 1.085–3.075) and time since HBsAg‐loss (HR 2.688, 95% CI 1.257–5.748). While increasing time since HBsAg‐loss increased the proportion of ELF‐defined fibrosis regression, increasing age was also associated with significant fibrosis. Age of achieving HBsAg‐loss (ageSC) was independently associated with high baseline ELF values. Up to 52.3% and 63.8% subjects with ageSC > 50 had advanced fibrosis/cirrhosis at baseline and 3 years, respectively, compared with 5.9% and 20.6% in subjects with ageSC < 50.

Conclusion

Fibrosis regression occurred in a minority of subjects achieving HBsAg‐loss, which was not significantly different compared with subjects with persistent overt CHB. Subjects after achieving HBsAg‐loss, especially among those with ageSC > 50, should receive ongoing surveillance for liver‐related complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Elasticity Imaging TechniquesLiver CirrhosisHepatitis B Surface AntigensHepatitis B, ChronicHumansMaleMiddle AgedFemaleProspective StudiesCase-Control StudiesAgedAdult

Stichwörter der Autor:innen

AgeChronic viral hepatitisFibrosis regressionFunctional cureHBV

Substanzen

Hepatitis B Surface Antigens

Autor:innen und Institutionen

  • Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
  • State Key Laboratory of Liver Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

ORCID-Profile: Lung-Yi Mak, Rex Wan-Hin Hui, Matthew S H Chung, Wai-Kay Seto, Man-Fung Yuen

Förderung

  • Health and Medical Research Fund of the Hong Kong Special Administrative Region

Zitieren

APA

Mak, L. Y., Hui, R. W., Chung, M. S. H., Wong, D. K., Fung, J., Seto, W. K., & Yuen, M. F. (2024). Regression of liver fibrosis after HBsAg loss: A prospective matched case–control evaluation using transient elastography and serum enhanced liver fibrosis test. Journal of Gastroenterology and Hepatology, 39(12), 2826-2834. https://doi.org/10.1111/jgh.16728

Vancouver

Mak LY, Hui RW, Chung MSH, Wong DK, Fung J, Seto WK, et al. Regression of liver fibrosis after HBsAg loss: A prospective matched case–control evaluation using transient elastography and serum enhanced liver fibrosis test. Journal of Gastroenterology and Hepatology. 2024;39(12):2826-2834. doi:10.1111/jgh.16728

BibTeX
@article{Mak2024,
  author = {Mak, Lung-Yi and Hui, Rex Wan-Hin and Chung, Matthew S H and Wong, Danny Ka-Ho and Fung, James and Seto, Wai-Kay and Yuen, Man-Fung},
  title = {Regression of liver fibrosis after HBsAg loss: A prospective matched case–control evaluation using transient elastography and serum enhanced liver fibrosis test},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  volume = {39},
  number = {12},
  pages = {2826--2834},
  doi = {10.1111/jgh.16728}
}
Kostenlos starten →